GFAP and Alzheimer disease: MMF treatment effectively suppressed the activation of Iba-1+ microglia and GFAP+ astrocytes in the hippocampus (Figures 1F–H), key cellular mediators of neuroinflammation in AD, consistent with a reduction in neuroinflammation.